Lesion Detection, Segmentation and Prediction in Multiple Sclerosis Clinical Trials

Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review

Multiple sclerosis (MS) is a demyelinating neurological disorder with a highly heterogeneous clinical presentation and course of progression. Disease-modifying therapies are the only available treatment, as there is no known cure for the disease. Careful selection of suitable therapies is necessary, as they can be accompanied by serious risks and adverse effects such as infection. Magnetic resonance imaging (MRI) plays a central role in the diagnosis and management of MS, though MRI lesions have displayed only moderate associations with MS clinical outcomes, known as the clinico-radiological paradox. With the advent of machine learning (ML) in healthcare, the predictive power of MRI can be improved by leveraging both traditional and advanced ML algorithms capable of analyzing increasingly complex patterns within neuroimaging data. The purpose of this review was to examine the application of MRI-based ML for prediction of MS disease progression. Studies were divided into five main categories: predicting the conversion of clinically isolated syndrome to MS, cognitive outcome, EDSS-related disability, motor disability and disease activity. The performance of ML models is discussed along with highlighting the influential MRI-derived biomarkers. Overall, MRI-based ML presents a promising avenue for MS prognosis. However, integration of imaging biomarkers with other multimodal patient data shows great potential for advancing personalized healthcare approaches in MS.

Recent advances in the longitudinal segmentation of multiple sclerosis lesions on magnetic resonance imaging: a review

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by demyelinating lesions that are often visible on magnetic resonance imaging (MRI). Segmentation of these lesions can provide imaging biomarkers of disease burden that can help monitor disease progression and the imaging response to treatment. Manual delineation of MRI lesions is tedious and prone to subjective bias, while automated lesion segmentation methods offer objectivity and speed, the latter being particularly important when analysing large datasets. Lesion segmentation can be broadly categorised into two groups: cross-sectional methods, which use imaging data acquired at a single time-point to characterise MRI lesions; and longitudinal methods, which use imaging data from the same subject acquired at two or more different time-points to characterise lesions over time. The main objective of longitudinal segmentation approaches is to more accurately detect the presence of new MS lesions and the growth or remission of existing lesions, which may be effective biomarkers of disease progression and treatment response. This paper reviews articles on longitudinal MS lesion segmentation methods published over the past 10 years. These are divided into traditional machine learning methods and deep learning techniques. PubMed articles using longitudinal information and comparing fully automatic two time point segmentations in any step of the process were selected. Nineteen articles were reviewed. There is an increasing number of deep learning techniques for longitudinal MS lesion segmentation that are promising to help better understand disease progression.

Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system, characterized by the appearance of focal lesions in the white and gray matter that topographically correlate with an individual patients neurological symptoms and signs. Magnetic resonance imaging (MRI) provides detailed in-vivo structural information, permitting the quantification and categorization of MS lesions that critically inform disease management. Traditionally, MS lesions have been manually annotated on 2D MRI slices, a process that is inefficient and prone to inter-/intra-observer errors. Recently, automated statistical imaging analysis techniques have been proposed to detect and segment MS lesions based on MRI voxel intensity. However, their effectiveness is limited by the heterogeneity of both MRI data acquisition techniques and the appearance of MS lesions. By learning complex lesion representations directly from images, deep learning techniques have achieved remarkable breakthroughs in the MS lesion segmentation task. Here, we provide a comprehensive review of state-of-the-art automatic statistical and deep-learning MS segmentation methods and discuss current and future clinical applications. Further, we review technical strategies, such as domain adaptation, to enhance MS lesion segmentation in real-world clinical settings.

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

BACKGROUND

The Oxford Big Data Institute, multiple sclerosis (MS) physicians and Novartis aim to address unresolved questions in MS with a novel comprehensive clinical trial data set.

OBJECTIVE

The objective of this study is to describe the Novartis-Oxford MS (NO.MS) data set and to explore the relationships between age, disease activity and disease worsening across MS phenotypes.

METHODS

We report key characteristics of NO.MS. We modelled MS lesion formation, relapse frequency, brain volume change and disability worsening cross-sectionally, as a function of patients' baseline age, using phase III study data (≈8000 patients).

RESULTS

NO.MS contains data of ≈35,000 patients (>200,000 brain images from ≈10,000 patients), with >10 years follow-up. (1) Focal disease activity is highest in paediatric patients and decreases with age, (2) brain volume loss is similar across age and phenotypes and (3) the youngest patients have the lowest likelihood (<25%) of disability worsening over 2 years while risk is higher (25%-75%) in older, disabled or progressive MS patients. Young patients benefit most from treatment.

CONCLUSION

NO.MS will illuminate questions related to MS characterisation, progression and prognosis. Age modulates relapse frequency and, thus, the phenotypic presentation of MS. Disease worsening across all phenotypes is mediated by age and appears to some extent be independent from new focal inflammatory activity.